Among the biggest challenges in medical technology is the search for therapies to help patients regain body function after suffering a paralyzing spinal cord injury. Research in this area is producing some very promising theories and applications that eventually could lead to substantial breakthroughs. Teams of doctors and scientists continue to work diligently in what can be described as a dedicated, niche market, where the driving force is tied to the very basic medical goal of improving these patients' quality of life.
by Robert Neil
Among the biggest challenges in medical technology is the search for therapies to help patients regain body function after suffering...
Join thousands of industry professionals who rely on Medtech Insight for daily insights
Already a subscriber?
Terumo will acquire OrganOx for about $1.5bn, adding the only FDA-cleared liver normothermic perfusion device to its portfolio. Analysts don’t expect the buyout to have a significant impact on competition, but the deal marks a strategic shift for Terumo into transplant medicine.
A Johns Hopkins University study found publicly traded companies are responsible for 90% of recalled AI-powered medical devices. The study attributes this link to lower clinical validation, especially among smaller companies, and advocates for increased clinical trials to enhance device safety.
Medicare’s device coverage process is “a system in crisis,” consultant Bruce Quinn warned at the NextGen Dx Summit. He criticized bloated NCDs, stalled advisory committees, and years-long delays, urging CMS to streamline LCDs and adopt a six-month “fast-track” model to speed innovation access.
